The global pain management therapeutics market size was USD 81.85 billion in 2023, calculated at USD 84.96 billion in 2024 and is expected to reach around USD 123.37 billion by 2034, expanding at a CAGR of 3.8% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
5.1. Covid-19: Pain Management Therapeutics Industry Impact
5.2. Pain Management Therapeutics Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Pain Management Therapeutics Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Pain Management Therapeutics Market Players to deal with Covid-19 Pandemic Scenario
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Growing prevalence of chronic disorders
6.1.1.2. Increasing geriatric population
6.1.2. Market Restraints
6.1.2.1. Side-effects associated with some pain management medications
6.1.3. Market Opportunities
6.1.3.1. Growing research and development expenditure
6.1.3.2. Technological advancements
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Pain Management Therapeutics Market Revenue by Market Players
7.1.1.2. Pain Management Therapeutics Market Revenue Market Share by Market Players
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Drug Class Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users
8.1. Pain Management Therapeutics Market, by Drug Class, 2024-2034
8.1.1. NSAIDs
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Opioids
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Anesthetics
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Antidepressants
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Anticonvulsants
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2034)
9.1. Pain Management Therapeutics Market, by Indication, 2024-2034
9.1.1. Arthritic Pain
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Neuropathic Pain
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Chronic Back Pain
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Post-Operative Pain
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Cancer Pain
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2021-2034)
10.1. Pain Management Therapeutics Market, by Distribution Channel, 2024-2034
10.1.1. Online Pharmacy
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Hospital Pharmacy
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue Forecast by Drug Class(2021-2034)
11.1.2. Market Revenue Forecast by Indication(2021-2034)
11.1.3. Market Revenue Forecast by Distribution Channel (2021-2034)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2021-2034)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2021-2034)
11.2. Europe
11.2.1. Market Revenue Forecast by Drug Class (2021-2034)
11.2.2. Market Revenue Forecast by Indication (2021-2034)
11.2.3. Market Revenue Forecast by Distribution Channel (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2021-2034)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2021-2034)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Drug Class (2021-2034)
11.3.2. Market Revenue Forecast by Indication (2021-2034)
11.3.3. Market Revenue Forecast by Distribution Channel (2021-2034)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2021-2034)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2021-2034)
11.4. LATAM
11.4.1. Market Revenue Forecast by Drug Class (2021-2034)
11.4.2. Market Revenue Forecast by Indication (2021-2034)
11.4.3. Market Revenue Forecast by Distribution Channel (2021-2034)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2021-2034)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2021-2034)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Drug Class (2021-2034)
11.5.2. Market Revenue Forecast by Indication (2021-2034)
11.5.3. Market Revenue Forecast by Distribution Channel (2021-2034)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2021-2034)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2021-2034)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2021-2034)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2021-2034)
12.1. Teva Pharmaceutical
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Distribution Channel
12.1.3. Revenue, Price, and Gross Margin
12.1.4. Recent Developments and Strategies
12.2. Pfizer
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Distribution Channel
12.2.3. Revenue, Price, and Gross Margin
12.2.4. Recent Developments and Strategies
12.3. Abbott
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Distribution Channel
12.3.3. Revenue, Price, and Gross Margin
12.3.4. Recent Developments and Strategies
12.4. Mallinckrodt Pharmaceuticals
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Distribution Channel
12.4.3. Revenue, Price, and Gross Margin
12.4.4. Recent Developments and Strategies
12.5. Endo International
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Distribution Channel
12.5.3. Revenue, Price, and Gross Margin
12.5.4. Recent Developments and Strategies
12.6. GlaxoSmithKline
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Distribution Channel
12.6.3. Revenue, Price, and Gross Margin
12.6.4. Recent Developments and Strategies
12.7. AstraZeneca
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Distribution Channel
12.7.3. Revenue, Price, and Gross Margin
12.7.4. Recent Developments and Strategies
12.8. Depomed
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Distribution Channel
12.8.3. Revenue, Price, and Gross Margin
12.8.4. Recent Developments and Strategies
12.9. Merck
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Distribution Channel
12.9.3. Revenue, Price, and Gross Margin
12.9.4. Recent Developments and Strategies
12.10. Novartis
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Distribution Channel
12.10.3. Revenue, Price, and Gross Margin
12.10.4. Recent Developments and Strategies
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample